New York Node

Principal Investigators:
Edward V. Nunes, M.D. [email]
Professor of Clinical Psychiatry
Columbia University, College of Physicians and Surgeons
1051 Riverside Dr., Box 51
New York, NY 10032

Jennifer McNeely, M.D., M.S. [email]
Associate Professor
New York University Grossman School of Medicine
180 Madison Avenue, 17th Floor
New York, NY 10016

Related Resources

NIDA web site

The New York Node was established in 2010 and originally named the Greater New York Node, created by combining into a single node both the Regional Research and Training Centers and the Community Treatment Programs of the original nodes in New York and Long Island. It was renamed the New York Node in 2020.

Grantee Institutions: New York State Psychiatric Institute, Columbia University and New York University School of Medicine

Protocol Involvement

• CTN-0001: Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
• CTN-0002: Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
• CTN-0003: Suboxone (Buprenorphine / Naloxone) Taper: A Comparison of Taper Schedules
• CTN-0007: Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics
• CTN-0008: Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
• CTN-0009: Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs
• CTN-0012: Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
• CTN-0015: Women’s Treatment for Trauma and Substance Use Disorders
• CTN-0016: Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment
• CTN-0018: Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
• CTN-0019: Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
• CTN-0021: Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
• CTN-0028: Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders
• CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD
• CTN-0030-A-1: Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
• CTN-0030: Prescription Opiate Abuse Treatment Study (POATS)
• CTN-0031-A-2: The Role of Alcohol Consumption in Classifications of Alcohol Use Disorders: A Clinical Study
• CTN-0037: Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
• CTN-0044-A-2: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044-A-3: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044: Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
• CTN-0045-Ot: Rates of HIV Testing and Barriers to Testing in African Americans Receiving Substance Abuse Treatment
• CTN-0047-A-1: Site Influences on Treatment Effects – Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)
• CTN-0047: Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
• CTN-0048-A-1: Pharmacogenetics of Buprenorphine/Naltrexone for Cocaine Dependence in the CURB Study
• CTN-0048: Cocaine Use Reduction with Buprenorphine (CURB)
• CTN-0051-A-1: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
• CTN-0051-A-2: Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
• CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
• CTN-0059: Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse Brief Screen/Assessment Tool (TAPS Tool)
• CTN-0062-Ot-A-1: Implementing the Tobacco, Alcohol, Prescription Medication, and Other Substances (TAPS) Tool in Rural Federally-Qualified Health Centers
• CTN-0062-Ot: A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements into the Electronic Health Record in Large Primary Care Settings (CDE-EHR-PC)
• CTN-0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
• CTN-0069-A-1: Retrospective Evaluation of Rapid Buprenorphine Induction in the Emergency Department for Opioid Use Disorder
• CTN-0069: Opioid Use Disorder in the Emergency Department (Project ED Health)
• CTN-0074-A-1: Primary Care Opioid Use Disorder (PROUD) Treatment Trial Economic Analysis Study
• CTN-0074: Primary Care Opioid Use Disorder (PROUD) Treatment Trial
• CTN-0079-A-1: Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine
• CTN-0079: Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)
• CTN-0082-A-1: COVID-19 Vaccine Readiness in People Who Use Substances in Community STI Clinics and Substance Use Intervention or Harm Reduction Programs in Eight Higher HIV Incidence Southeastern Cities
• CTN-0082: Implementation Survey of PrEP and Opioid Use Related Services In STI Clinics and Community Based Organizations (CBOs)
• CTN-0094: Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome
• CTN-0096: Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives
• CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder
• CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy
• CTN-0101: Subthreshold Opioid Use Disorder Prevention (STOP) Trial
• CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL)
• CTN-0122: Comprehensive Meta-Analysis of CTN Treatment Outcomes by Race and Sex
• CTN-0126: Longitudinal Follow-up of Individuals with Opioid Use Disorder
• CTN-0139: Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care)